{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-099413","form_type":"8-K/A","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.631609+00:00","generated_at":"2026-05-17T23:33:47.737819+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"EyePoint completes enrollment in both Phase 3 wet AMD trials for DURAVYU; topline data mid-2026","bullets":["LUCIA enrolled over 400 patients in 7 months; combined LUGANO and LUCIA total over 800 patients.","DSMC interim review confirmed safety consistent with prior trials; no protocol changes, continuation recommended.","Topline 56-week data for LUGANO expected mid-2026; LUCIA topline data to follow shortly after.","DURAVYU is sustained-release TKI with 6-month redosing; evaluated vs on-label aflibercept in non-inferiority design.","Phase 3 program aligned with FDA/EMA; NDA filing targeted after one-year efficacy and safety endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-099413","json":"https://secwatch.observer/filing/0000950170-25-099413.json","markdown":"https://secwatch.observer/filing/0000950170-25-099413.md","text":"https://secwatch.observer/filing/0000950170-25-099413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025099413/0000950170-25-099413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025099413/eypt-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:33:47.737819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}